Merck KGaA (ETR:MRK) Is Due To Pay A Dividend Of €2.20
Yahoo FinanceApr 28 03:28 ET
Merck Shareholders Approve Dividend of EUR2.20 Per Share At AGM
Merck Shareholders Approve Dividend of EUR2.20 Per Share At AGM
Dow JonesApr 26 10:48 ET
Merck Shareholders Elect New Supervisory Board at AGM
Merck Shareholders Elect New Supervisory Board at AGM
Dow JonesApr 26 10:47 ET
Shareholders Will Most Likely Find Merck KGaA's (ETR:MRK) CEO Compensation Acceptable
Yahoo FinanceApr 20 02:23 ET
MERCK KGAA SPON ADR EACH REPR 0.2 ORD SHS To Go Ex-Dividend On April 29th, 2024 With 0.47297 USD Dividend Per Share
April 6th - $MERCK KGAA SPON ADR EACH REPR 0.2 ORD SHS(MKKGY.US)$ is trading ex-dividend on April 29th, 2024. Shareholders of record on April 30th, 2024 will receive 0.47297 USD dividend per share
moomoo NewsApr 5 19:40 ET
Merck KGaA to Open $326 Mln Pharmaceutical Plant in South Korea to Expand in Asia
By David Sachs Merck KGaA will spend more than 300 million euros ($326 million) on a pharmaceutical plant in South Korea as part of its strategy to expand in Asia. The German drug-and-chemicals comp
WSJMar 20 11:27 ET
Merck KGaA Expected to Meet or Exceed Guidance This Year -- Market Talk
1044 GMT - Germany's Merck KGaA is well set up to meet or even exceed its guidance in the second half of the year, Stifel analysts Dylan Van Haaften and Ed Hall say in a research note. The German phar
WSJMar 7 05:44 ET
Merck KGaA: Co-Compiled Consensus Saw 2023 Pre-Items EPS at EUR8.45
Merck KGaA: Co-Compiled Consensus Saw 2023 Pre-Items EPS at EUR8.45
Dow JonesMar 7 01:00 ET
Merck KGaA Sees Slight to Moderate Organic Growth in Sales, Pre-Items EBITDA in 2024
Merck KGaA Sees Slight to Moderate Organic Growth in Sales, Pre-Items EBITDA in 2024
Dow JonesMar 7 01:00 ET
Merck KGaA: Analysts Saw 2023 Profit After Tax at EUR2.81B
Merck KGaA: Analysts Saw 2023 Profit After Tax at EUR2.81B
Dow JonesMar 7 01:00 ET
Merck KGaA Keeps Dividend at EUR2.20 Vs EUR2.20
Merck KGaA Keeps Dividend at EUR2.20 Vs EUR2.20
Dow JonesMar 7 01:00 ET
Merck KGaA 2023 Pre-Items EBITDA EUR5.88B
Merck KGaA 2023 Pre-Items EBITDA EUR5.88B
Dow JonesMar 7 01:00 ET
MORNING BID EUROPE-ECB Also Wants More Evidence
Yahoo FinanceMar 7 00:30 ET
Express News | C4 Therapeutics Has Entered Into A License Agreement With Merck KGaA, To Exclusively Discover Two Targeted Protein Degraders Against Critical Oncogenic Proteins, C4 Therapeutics Will Receive $16M As Upfront And Is Eligible Of Up $740M In Milestone Payment
Moomoo 24/7Mar 4 07:05 ET
Merck KGaA Supervisory Board Elects Michael Kleinemeier as Chair
Merck KGaA Supervisory Board Elects Michael Kleinemeier as Chair
Dow JonesFeb 8 03:02 ET
Merck KGaA to Grow Investment in South Korea Amid Hope of Semiconductor Market Rebound in FY24
Merck KGaA (MRK.F) is planning to grow its investment in South Korea amid hope that the global semiconductor market will rebound in 2024, Yonhap News Agency reported Friday, citing Chief Commercial Officer Anand Nambiar.
MT NewswiresFeb 2 03:20 ET
Merck KGaA Supervisory Board Chairman Wolfgang Buechele to Step Down
By Adria Calatayud Germany's Merck KGaA said Supervisory Board Chairman Wolfgang Buechele will step down from his role and become chairman of the board of partners of the Merck family's holding compa
WSJJan 29 03:48 ET
4 Pharma Stocks to Buy, According to an Analyst. Novo Nordisk Isn't One. -- Barrons.com
Adam Clark The European pharmaceutical sector looks set for a good year on strong cash flows and attractive valuations, according to UBS analysts. They picked out four stocks that could particularly
Barron'sJan 16 07:43 ET
Novartis to Buy Autoimmune Drug Developer Calypso Biotech
Seeking AlphaJan 8 11:54 ET
Merck KGaA's Trial Miss Signals High Bar for Multiple Sclerosis Studies -- Market Talk
Merck KGaA's failed late-stage clinical studies for its evobrutinib experimental drug in multiple sclerosis suggests similar drug candidates will have to clear a high bar, Jefferies analysts say in a research note.
Dow JonesDec 7, 2023 03:30 ET
No Data
No Data